Iatrogenic botulism

Summary

Iatrogenic botulism (MONDO:0016778) is a disease and 1 clinical trial. Top therapeutic interventions include amifampridine. A subtype of botulism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 13
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		180	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

13 HPO clinical features (Orphanet curated; top 13 by frequency):

HPO ID	Term	Frequency
HP:0000217	Xerostomia	Very frequent (80-99%)
HP:0000508	Ptosis	Very frequent (80-99%)
HP:0001278	Orthostatic hypotension	Very frequent (80-99%)
HP:0001324	Muscle weakness	Very frequent (80-99%)
HP:0002015	Dysphagia	Very frequent (80-99%)
HP:0006597	Diaphragmatic paralysis	Very frequent (80-99%)
HP:0006824	Cranial nerve paralysis	Very frequent (80-99%)
HP:0011499	Mydriasis	Very frequent (80-99%)
HP:0012378	Fatigue	Very frequent (80-99%)
HP:0100021	Cerebral palsy	Very frequent (80-99%)
HP:0000016	Urinary retention	Frequent (30-79%)
HP:0002019	Constipation	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	iatrogenic botulism
Mondo ID	MONDO:0016778
Orphanet	254509
ICD-11	230654666
NCIT	C128345
UMLS	C4288922
MedGen	926454
GARD	0020747
Is cancer (heuristic)	no

Also known as: accidental botulism · inadvertent botulism

Disease family

This is a subtype of botulism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › botulism › iatrogenic botulism

Related subtypes (3): foodborne botulism, toxin-mediated infectious botulism, inhalational botulism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05769478	PHASE1	COMPLETED	Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AMIFAMPRIDINE	4	1